Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Business Achievements

Catalyst Pharmaceuticals Joins Russell 3000 Index

Monday, June 26, 2017   (0 Comments)
Share |

Catalyst Pharmaceuticals Joins Russell 3000 Index


CORAL GABLES, Fla., June 26, 2017 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, today announced that the company has been added to the broad-market Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted June 9.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of the end of May, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

"We are pleased that Catalyst Pharmaceuticals has been added as a member of the Russell 3000®," commented Patrick McEnany, president and chief executive officer. "This membership validates our recent strategy and will enhance our visibility in the investment community." Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $8.4 trillion in assets are benchmarked against Russell’s US indexes.Russell indexes are part of FTSE Russell, a leading global index provider.


About FTSE Russell

FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.


About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis and infantile spasms. Firdapse® has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of LEMS and Orphan Drug Designation for LEMS, CMS and myasthenia gravis. Firdapse is the first and only approved drug in Europe for symptomatic treatment in adults with LEMS.

Catalyst is also developing CPP-115 to treat refractory infantile spasms, and possibly refractory Tourette's Disorder. CPP-115 has been granted U.S. Orphan Drug Designation for the treatment of infantile spasms by the FDA and has been granted E.U. Orphan Medicinal Product Designation for the treatment of West syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).


Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and
unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ
materially from forecasted results. A number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2016 and its other filings with the U.S. Securities and
Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from
Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which
speaks only as of this date.


Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com

Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com

###


Abbott

BioFlorida, Inc. | 6742 Forest Hill Blvd., Suite 256 | West Palm Beach, FL 33413
(P) 561-653-3839 admin@bioflorida.com
Membership Management Software Powered by YourMembership  ::  Legal